1、 EVERNORTH RESEARCH INSTITUTEPharmacy in Focus:Navigating the GLP-1 conundrumDemand,cost and sustainabilityTogether,we can foster partnerships,streamline solutions and deliver care that is accessible,sustainable,and effective.INTRODUCTIONAn in-depth look at the state of the GLP-1 marketWe are please

2、d to present the latest Pharmacy in Focus report,Navigating the GLP-1 conundrum:Demand,cost and sustainability,a report analyzing the growing use of GLP-1 therapies.These drugs offer significant benefits for chronic conditions like diabetes and obesity,but their increasing popularity raises critical

3、 issues.Our goal is to help you navigate this evolving space.From understanding how these therapies work to exploring their financial and logistical implications,this report aims to spark thoughtful conversation and drive meaningful action.As you review this report,we invite you to consider how your

4、 work can contribute to the future of GLP-1 therapies for the patients who need them most.Together,we can foster partnerships,streamline solutions and deliver care that is accessible,effective and sustainable.With a strong focus on making the system better and a shared commitment to improving health

5、 outcomes,we thank you for your continued support and engagement.Together,we can drive health and vitality forward and shape a better future.In good health,Urvashi Patel,PhD,MPH Vice President,Evernorth Research InstituteEVERNORTH HEALTH SERVICESNAVIGATING THE GLP-1 CONUNDRUM|2The evolving pharmacy

6、landscapeThe pharmacy industry is at the epicenter of a worldwide transformative shift in health care.In the U.S.,prescription drug spending has grown steadily to$723 billion in 2023.1 For commercial plans,Evernorth Research Institute found that prescription drug spend has seen increases ranging fro